Alimena G - Search Results

1

Response of prostate cancer during imatinib therapy in a patient with chronic myeloid leukemia.

Breccia M, De Cuia MR, D'Elia GM, Francesca B, Mandelli F, Alimena G. Breccia M, et al. Among authors: alimena g. Haematologica. 2004 Jul;89(7):ECR20. Haematologica. 2004. PMID: 15257957 No abstract available.

2

Extramedullary blast crisis occurring in a Philadelphia-positive chronic myeloid leukemia patient with major cytogenetic response to imatinib.

Breccia M, Nanni M, Mancini F, Russo E, Mecarocci S, Alimena G. Breccia M, et al. Among authors: alimena g. Haematologica. 2004 Apr;89(4):ECR11. Haematologica. 2004. PMID: 15075103 No abstract available.

3

Sudden blast crisis in patients with Philadelphia chromosome-positive chronic myeloid leukemia who achieved complete cytogenetic remission after imatinib therapy.

Alimena G, Breccia M, Latagliata R, Carmosino I, Russo E, Biondo F, Diverio D, Mancini M, Nanni M, Mandelli F. Alimena G, et al. Cancer. 2006 Sep 1;107(5):1008-13. doi: 10.1002/cncr.22046. Cancer. 2006. PMID: 16878324 Free article.

4

Atypical chronic myeloid leukaemia with CD117-positive blast cells treated with imatinib: A report of two cases.

Breccia M, Russo E, De Propris MS, Frustaci A, Alimena G. Breccia M, et al. Among authors: alimena g. Acta Haematol. 2006;116(3):211-2. doi: 10.1159/000094684. Acta Haematol. 2006. PMID: 17016042 No abstract available.

5

Cocaine abuse may influence the response to imatinib in CML patients.

Breccia M, Gentilini F, Alimena G. Breccia M, et al. Among authors: alimena g. Haematologica. 2007 Mar;92(3):e41-2. doi: 10.3324/haematol.10976. Haematologica. 2007. PMID: 17405756 Free article. No abstract available.

6

Nilotinib can override dasatinib resistance in chronic myeloid leukemia patients with secondary resistance to imatinib first-line therapy.

Breccia M, Cannella L, Nanni M, Stefanizzi C, Alimena G. Breccia M, et al. Among authors: alimena g. Acta Haematol. 2007;118(3):162-4. doi: 10.1159/000108639. Epub 2007 Sep 20. Acta Haematol. 2007. PMID: 17890849 No abstract available.

7

Resistance to imatinib in chronic myeloid leukemia and therapeutic approaches to circumvent the problem.

Breccia M, Alimena G. Breccia M, et al. Among authors: alimena g. Cardiovasc Hematol Disord Drug Targets. 2009 Mar;9(1):21-8. doi: 10.2174/187152909787581363. Cardiovasc Hematol Disord Drug Targets. 2009. PMID: 19275574 Review.

8

The metabolic consequences of imatinib mesylate: Changes on glucose, lypidic and bone metabolism.

Breccia M, Alimena G. Breccia M, et al. Among authors: alimena g. Leuk Res. 2009 Jul;33(7):871-5. doi: 10.1016/j.leukres.2009.01.040. Leuk Res. 2009. PMID: 19307018 Review.

9

Nilotinib therapy in chronic myelogenous leukemia: the strength of high selectivity on BCR/ABL.

Breccia M, Alimena G. Breccia M, et al. Among authors: alimena g. Curr Drug Targets. 2009 Jun;10(6):530-6. doi: 10.2174/138945009788488468. Curr Drug Targets. 2009. PMID: 19519355 Review.

10

Nilotinib: a second-generation tyrosine kinase inhibitor for chronic myeloid leukemia.

Breccia M, Alimena G. Breccia M, et al. Among authors: alimena g. Leuk Res. 2010 Feb;34(2):129-34. doi: 10.1016/j.leukres.2009.08.031. Epub 2009 Sep 23. Leuk Res. 2010. PMID: 19783301 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

361 results

Search Page

Filters